Chromosome 6p Amplification in Aqueous Humor Cell-Free DNA Is a Prognostic Biomarker for Retinoblastoma Ocular Survival
Open Access
- 20 May 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (8) , 1166-1175
Abstract
Aqueous humor contains tumor-derived cell-free DNA (cfDNA) and can serve as a liquid biopsy for retinoblastoma. We previously associated somatic copy-number alteration (SCNA) 6p gain with a 10-fold increased risk of enucleation. Here we provide a 2-year update to further explore 6p gain as a prognostic biomarker for ocular survival. Patients diagnosed with retinoblastoma from December 2014 to July 2019 from whom aqueous humor was sampled were included. cfDNA was extracted and shallow whole-genome sequencing performed to identify highly recurrent retinoblastoma SCNAs (gain of 1q, 2p, 6p, loss of 13q, 16q). 116 aqueous humor samples from 50 eyes of 46 patients were included: 27 eyes were salvaged, 23 were enucleated. Highly recurrent retinoblastoma SCNAs were found in 66% eyes. 6p gain was the most prevalent SCNA (50% eyes). It was particularly more prevalent in enucleated eyes (73.9%) than in salvaged eyes (29.6%; P = 0.004). 6p gain in aqueous humor cfDNA portended nearly 10-fold increased odds of enucleation (OR = 9.87; 95% confidence interval = 1.75–55.65; P = 0.009). In the enucleated eyes, 6p gain was associated with aggressive histopathologic features, including necrosis, higher degrees of anaplasia, and focal invasion of ocular structures. With extended follow-up and nearly double the aqueous humor samples, we continue to demonstrate 6p gain as a potential prognostic biomarker for retinoblastoma.Implications: Aqueous humor is a high-yield source of tumor-derived DNA in retinoblastoma eyes. Detection of 6p gain in the aqueous humor allows for targeted, patient-centered therapies based on this molecular prognostic marker. Prospective, multicenter studies with aqueous humor sampled from all eyes at diagnosis are warranted to validate these findings.Keywords
All Related Versions
Funding Information
- NIH (K08CA232344)
- Hyundai Hope On Wheels (RGA012351)
- American Cancer Society (IRG-16-181-57)
- NIH (P30EY029220)
- NCI (P30CA014089)
This publication has 48 references indexed in Scilit:
- Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectivesSaudi Journal of Ophthalmology, 2013
- Fine‐needle aspiration biopsy and other biopsies in suspected intraocular malignant disease: a reviewActa Ophthalmologica, 2009
- One hit, two hits, three hits, more? Genomic changes in the development of retinoblastomaGenes, Chromosomes and Cancer, 2007
- Profiling genomic copy number changes in retinoblastoma beyond loss of RB1Genes, Chromosomes and Cancer, 2006
- Chromosome 6p amplification and cancer progressionJournal of Clinical Pathology, 2006
- A proposal for an international retinoblastoma staging systemPediatric Blood & Cancer, 2005
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005
- Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastomaOncogene, 2005
- Intraocular Retinoblastoma: the Case for a New Group ClassificationOphthalmology Clinics of North America, 2005
- Simultaneous chromosome 1q gain and 16q loss is associated with steroid receptor presence and low proliferation in breast carcinomaLaboratory Investigation, 2004